September 09, 2019
Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer
Media
September 06, 2019
Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study
September 04, 2019
Nordic Nanovector to participate in three upcoming investor conferences in the US
September 03, 2019
Strongbridge Biopharma plc to Present at the H.C. Wainwright 21st Annual Global Investment Conference and the Janney Montgomery Scott Healthcare Conference 2019
August 30, 2019
New updated data will be presented from Oncopeptides’ Pivotal Phase 2 HORIZON study in patients with extra medullary disease (EMD) on September 15th
August 29, 2019
Nordic Nanovector ASA: Invitation to R&D Day in Oslo and Webcast
August 28, 2019
Interim Report Q2 2019
August 28, 2019
Pulmonx Announces that Priority Health Now Covers the Zephyr Valve, a Less Invasive Treatment Option for Severe Emphysema (COPD)
August 22, 2019
Nordic Nanovector ASA – Results for the Second Quarter and First Half 2019
August 22, 2019
Targovax ASA: Second quarter and first half 2019 results
